GamaMabs Pharma
A clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.
GamaMabs' lead project is the monoclonal antibody (mAb) GM102, which targets anti-müllerian human receptor II, an unaddressed specific target in cancer.
The company develops low-fucose EMABling antibodies with increased tumor cell killing properties through the activation of immune system cells.
GamaMabs has a licensing agreement with MedImmune to develop an antibody drug conjugate targeting cancer.
The company was founded in 2013 in France.
Latest GamaMabs Pharma News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze